IDEAYA Biosciences, Inc. , a leading precision medicine oncology company, provided a business update and announced financial results for the first quarter ended March 31, ...

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation ...

Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...

Five novel inhibitors of the MenT3 toxin were identified through a machine learning and simulations pipeline, offering new ...

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced ...

Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work ...

Resolving the mechanism of RXR ligand-dependent NR4A-RXR nuclear receptor heterodimer activation requires a diverse ligand set that includes heterodimer-selective agonists.

Mortality disparities among people of different genetic ancestries are increasing, highlighting the need for more diverse ...

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

However, maintaining the stability of liquid biological products can be challenging. Many protein types, including monoclonal antibodies, multispecific antibodies, antibody fragments, fusion proteins, ...

Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA ...